Fig. 4From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET studyImprovements in CRT from baseline to end of the study. CRT central retinal thickness, ITT intent-to-treat population, PP per-protocol populationBack to article page